| Nicholas M Romansky, DPM | |
|
101 N Monroe St, Media, PA 19063-3037 | |
| (610) 565-3668 | |
| (610) 565-9722 |
| Full Name | Nicholas M Romansky |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 40 Years |
| Location | 101 N Monroe St, Media, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912992991 | NPI | - | NPPES |
| 0097358000 | Other | PA | KEYSTONE HEALTH PLAN EAST |
| 01101572-01 | Other | PA | AMERICHOICE-PHOENIXVILLE |
| 7071841 | Other | PA | CIGNA |
| D00503 | Other | PA | AHA (AMERIHEALTH ADMINIST |
| 000786653 | Other | PA | GREAT WEST |
| 01101572-02 | Other | PA | AMERICHOICE MEDIA OFFICE |
| 265239 | Other | PA | MAMSI |
| 480012888 | Other | PA | RAILROAD MEDICARE |
| 362910 | Other | PA | UNITED HEALTHCARE |
| 0097358000 | Other | PA | PERSONAL CHOICE |
| 400503 | Other | PA | PA BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | SC003145L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Paoli Hospital | Paoli, PA | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Bryn Mawr Hospital | Bryn mawr, PA | Hospital |
| Crozer Chester Medical Center | Upland, PA | Hospital |
| Riddle Memorial Hospital | Media, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Novacare Outpatient Rehabilitation East Inc | 3678480290 | 617 |
| Healthmark Foot And Ankle Associates, P.c. | 4981684925 | 5 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
The researchers found that smoking is responsible for 467,000 premature deaths each year, high blood pressure for 395,000, and being overweight for 216,000. The effects of smoking work out to be about one in five deaths in American adults, while high blood pressure is responsible for one in six deaths.
Patients' self-rated health is a better long-term predictor of illness and death than standard blood tests, blood pressure measurements or other symptomatic evidence a doctor might gather, according to a new study from Rice University.
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.
› Verified 8 days ago
| Provider Name | Healthmark Foot And Ankle Associates, P.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1255376307 PECOS PAC ID: 4981684925 Enrollment ID: O20040721001104 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
The researchers found that smoking is responsible for 467,000 premature deaths each year, high blood pressure for 395,000, and being overweight for 216,000. The effects of smoking work out to be about one in five deaths in American adults, while high blood pressure is responsible for one in six deaths.
Patients' self-rated health is a better long-term predictor of illness and death than standard blood tests, blood pressure measurements or other symptomatic evidence a doctor might gather, according to a new study from Rice University.
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas M Romansky, DPM 101 N Monroe St, Media, PA 19063-3037 Ph: (610) 565-3668 | Nicholas M Romansky, DPM 101 N Monroe St, Media, PA 19063-3037 Ph: (610) 565-3668 |
News Archive
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
The researchers found that smoking is responsible for 467,000 premature deaths each year, high blood pressure for 395,000, and being overweight for 216,000. The effects of smoking work out to be about one in five deaths in American adults, while high blood pressure is responsible for one in six deaths.
Patients' self-rated health is a better long-term predictor of illness and death than standard blood tests, blood pressure measurements or other symptomatic evidence a doctor might gather, according to a new study from Rice University.
Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.
› Verified 8 days ago
Dr. Todd Rice, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 101 N Monroe St, Media, PA 19063 Phone: 610-595-3668 Fax: 610-565-9722 | |
Dr. John A Pron, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1118 W Baltimore Pike Ste 100, Media, PA 19063 Phone: 484-227-8370 Fax: 484-227-1645 | |
David C Erfle, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 101 N Monroe St, Media, PA 19063 Phone: 610-565-3668 Fax: 610-565-9722 | |
Colin P Flannery, D.P.M Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 101 N Monroe St, Media, PA 19063 Phone: 610-565-3668 Fax: 610-565-9722 | |
Healthmark Foot And Ankle Associates, P.c. Podiatrist Medicare: Medicare Enrolled Practice Location: 101 N Monroe St, Media, PA 19063 Phone: 610-565-3668 Fax: 610-565-9722 | |
Sutera & Jones Surgical Podiatry, P.c. Podiatrist Medicare: Medicare Enrolled Practice Location: 280 N Providence Rd, Upper Level, Media, PA 19063 Phone: 610-566-4383 Fax: 610-566-1856 | |
Dr. Angelo B Sutera Jr., DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 280 N Providence Rd Ste 103, Media, PA 19063 Phone: 610-566-4563 Fax: 610-566-1856 |